For immediate release –
Junction City, KS Last week, Ventria Bioscience Inc. obtained an important win in its effort to stop the importation and sale of infringing recombinant albumin made in China by Wuhan Healthgen Biotechnology Corp. On August 18, 2021, the U.S. International Trade Commission (ITC) formally found three U.S. distributors of such products—Aspira Scientific, Inc. (a/k/a Aspira Chemical), eEnzyme LLC, and ScienCell Research Laboratories, Inc.—to be in default, which should soon preclude them from importing or selling the Chinese rHSA in the United States.
In January 2021, the ITC launched an investigation to determine whether Recombinant Albumin produced by Wuhan Healthgen infringes U.S. patents owned by Ventria, and/or is being unlawfully marketed and sold without identifying its Chinese country of origin. Neither Aspira, eEnzyme, nor ScienCell contested these allegations before the ITC. Thus, the facts and contentions presented by Ventria are presumed to be true with respect to these three companies, and the ITC has announced that they are officially in default.
Two other companies that had previously distributed Wuhan Healthgen’s product —US Biological Corp. and antibodies-online, Inc.—settled with Ventria immediately and agreed to cease importing and selling the Chinese product. Thus, none of the distributors included in Ventria’s ITC action has stood to defend Wuhan Healthgen’s products.
Ventria’s patented, plant-derived Recombinant Albumin is the first plant produced product introduced into the market. It was developed and made entirely in the USA at Ventria’s facilities in accordance with rigorous scientific and manufacturing standards. The ITC case is Certain Plant-Derived Recombinant Human Serum Albumins (rHSA) and Products Containing Same, Inv. No. 337-TA-1238. Ventria has also sued Wuhan Healthgen for patent infringement in federal district court.
Questions about this press release can be directed to Ventria Bioscience Inc. at Info@Ventria.com.